{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:20:33Z","timestamp":1790774433412,"version":"4.1.0"},"reference-count":41,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2017,2,3]],"date-time":"2017-02-03T00:00:00Z","timestamp":1486080000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0171205","type":"journal-article","created":{"date-parts":[[2017,2,3]],"date-time":"2017-02-03T18:40:44Z","timestamp":1486147244000},"page":"e0171205","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":50,"title":["A single-arm, open-label, phase 2 clinical trial evaluating disease response following treatment with BI-505, a human anti-intercellular adhesion molecule-1 monoclonal antibody, in patients with smoldering multiple myeloma"],"prefix":"10.1371","volume":"12","author":[{"given":"Stina","family":"Wichert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunnar","family":"Juliusson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c5sa","family":"Johansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Sonesson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Teige","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Teige","family":"Wickenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f6rn","family":"Frendeus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magnus","family":"Korsgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Hansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2017,2,3]]},"reference":[{"issue":"24","key":"ref1","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1056\/NEJM198006123022405","article-title":"Smoldering Multiple-Myeloma","volume":"302","author":"RA Kyle","year":"1980","journal-title":"New Engl J Med"},{"issue":"4","key":"ref2","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1200\/JCO.2009.22.2257","article-title":"Smoldering (asymptomatic) multiple myeloma: current diagnostic criteria, new predictors of outcome, and follow-up recommendations","volume":"28","author":"J Blade","year":"2010","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"issue":"25","key":"ref3","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1056\/NEJMoa070389","article-title":"Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma","volume":"356","author":"RA Kyle","year":"2007","journal-title":"New Engl J Med"},{"issue":"1","key":"ref4","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/leu.2008.291","article-title":"Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma","volume":"23","author":"RA Kyle","year":"2009","journal-title":"Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, UK"},{"key":"ref5","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) and smoldering myeloma (SMM): a practical guide to management","author":"N Maciocia","year":"2016","journal-title":"Hematological oncology"},{"issue":"5","key":"ref6","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa1300439","article-title":"Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma","volume":"369","author":"MV Mateos","year":"2013","journal-title":"The New England journal of medicine"},{"issue":"12","key":"ref7","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"SV Rajkumar","year":"2014","journal-title":"The Lancet Oncology"},{"issue":"10","key":"ref8","doi-asserted-by":"crossref","first-page":"4469","DOI":"10.4049\/jimmunol.1400135","article-title":"ICAM-1: isoforms and phenotypes","volume":"192","author":"TN Ramos","year":"2014","journal-title":"Journal of immunology"},{"issue":"11","key":"ref9","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1038\/nri3908","article-title":"How leukocytes cross the vascular endothelium","volume":"15","author":"D Vestweber","year":"2015","journal-title":"Nature Reviews Immunology"},{"issue":"8","key":"ref10","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/nrc2189","article-title":"Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets","volume":"7","author":"T Hideshima","year":"2007","journal-title":"Nature reviews Cancer"},{"issue":"8","key":"ref11","first-page":"991","article-title":"Expression of eight genes of nuclear factor-kappa B pathway in multiple myeloma using bone marrow aspirates obtained at diagnosis","volume":"24","author":"MS Sampaio","year":"2009","journal-title":"Histology and histopathology"},{"issue":"4","key":"ref12","first-page":"218","article-title":"Evidence for cell adhesion-mediated drug resistance of multiple myeloma cells in vivo","volume":"21","author":"R Schmidmaier","year":"2006","journal-title":"The International journal of biological markers"},{"issue":"3","key":"ref13","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1038\/leu.2012.272","article-title":"PSGL-1\/selectin and ICAM-1\/CD18 interactions are involved in macrophage-induced drug resistance in myeloma","volume":"27","author":"Y Zheng","year":"2013","journal-title":"Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, UK"},{"issue":"3","key":"ref14","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0171-2985(88)80071-8","article-title":"The Melanoma Progression-Associated Antigen P3.58 Is Identical to the Intercellular-Adhesion Molecule, Icam-1","volume":"178","author":"JP Johnson","year":"1988","journal-title":"Immunobiology"},{"issue":"3","key":"ref15","first-page":"610","article-title":"Anti-Cd54 (Icam-1) Has Antitumor-Activity in Scid Mice with Human Myeloma Cells","volume":"55","author":"YW Huang","year":"1995","journal-title":"Cancer research"},{"issue":"4","key":"ref16","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.ccr.2013.02.026","article-title":"A human ICAM-1 antibody isolated by a function-first approach has potent macrophage-dependent antimyeloma activity in vivo","volume":"23","author":"N Veitonmaki","year":"2013","journal-title":"Cancer cell"},{"issue":"12","key":"ref17","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1158\/1078-0432.CCR-14-3090","article-title":"A Phase I Dose-Escalation Study of Antibody BI-505 in Relapsed\/Refractory Multiple Myeloma","volume":"21","author":"M Hansson","year":"2015","journal-title":"Clinical cancer research: an official journal of the American Association for Cancer Research"},{"key":"ref18","article-title":"Immune responses in multiple myeloma: role of the natural immune surveillance and potential of immunotherapies","author":"C Guillerey","year":"2016","journal-title":"Cellular and molecular life sciences: CMLS"},{"issue":"4","key":"ref19","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s11899-015-0283-0","article-title":"Immunotherapy for Multiple Myeloma, Past, Present, and Future: Monoclonal Antibodies, Vaccines, and Cellular Therapies","volume":"10","author":"R Karp Leaf","year":"2015","journal-title":"Current hematologic malignancy reports"},{"issue":"5","key":"ref20","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1046\/j.1365-2141.1998.00930.x","article-title":"Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant","volume":"102","author":"J Blade","year":"1998","journal-title":"British journal of haematology"},{"issue":"2","key":"ref21","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1600-0609.1993.tb00148.x","article-title":"Initial versus deferred melphalan-prednisone therapy for asymptomatic multiple myeloma stage I\u2014a randomized study. Myeloma Group of Western Sweden","volume":"50","author":"M Hjorth","year":"1993","journal-title":"European journal of haematology"},{"issue":"7","key":"ref22","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1054\/bjoc.1999.1087","article-title":"Long-term survival of stage I multiple myeloma given chemotherapy just after diagnosis or at progression of the disease: a multicentre randomized study","volume":"82","author":"A Riccardi","year":"2000","journal-title":"Brit J Cancer"},{"issue":"10","key":"ref23","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1002\/ajh.21821","article-title":"Long-term results of single-agent thalidomide as initial therapy for asymptomatic (smoldering or indolent) myeloma","volume":"85","author":"K Detweiler-Short","year":"2010","journal-title":"Am J Hematol"},{"issue":"8","key":"ref24","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1182\/blood-2008-06-164228","article-title":"Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease","volume":"112","author":"B Barlogie","year":"2008","journal-title":"Blood"},{"issue":"1","key":"ref25","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/leu.2012.236","article-title":"A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma","volume":"27","author":"TE Witzig","year":"2013","journal-title":"Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, UK"},{"issue":"5","key":"ref26","doi-asserted-by":"crossref","first-page":"771","DOI":"10.3109\/10428194.2011.553000","article-title":"Pamidronate versus observation in asymptomatic myeloma: final results with long-term follow-up of a randomized study","volume":"52","author":"G D'Arena","year":"2011","journal-title":"Leukemia & lymphoma"},{"issue":"1","key":"ref27","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1046\/j.1365-2141.2002.03549.x","article-title":"Pamidronate induces bone formation in patients with smouldering or indolent myeloma, with no significant anti-tumour effect","volume":"118","author":"A Martin","year":"2002","journal-title":"British journal of haematology"},{"issue":"16","key":"ref28","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1200\/JCO.2003.99.248","article-title":"Pamidronate for early-stage, untreated myeloma","volume":"21","author":"P Musto","year":"2003","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"issue":"7","key":"ref29","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1002\/cncr.23783","article-title":"A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma","volume":"113","author":"P Musto","year":"2008","journal-title":"Cancer"},{"issue":"2","key":"ref30","doi-asserted-by":"crossref","first-page":"114","DOI":"10.4065\/84.2.114","article-title":"Induction of a Chronic Disease State in Patients With Smoldering or Indolent Multiple Myeloma by Targeting Interleukin 1 beta-Induced Interleukin 6 Production and the Myeloma Proliferative Component","volume":"84","author":"JA Lust","year":"2009","journal-title":"Mayo Clin Proc"},{"issue":"6","key":"ref31","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1001\/jamaoncol.2015.2010","article-title":"Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma","volume":"1","author":"N Korde","year":"2015","journal-title":"JAMA oncology"},{"issue":"2","key":"ref32","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/ijc.21829","article-title":"Rapid induction of apoptosis in B-cell lymphoma by functionally isolated human antibodies","volume":"119","author":"J Fransson","year":"2006","journal-title":"International journal of cancer"},{"issue":"8","key":"ref33","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1212\/WNL.57.8.1428","article-title":"Use of anti-ICAM-1 therapy in ischemic stroke: results of the Enlimomab Acute Stroke Trial","volume":"57","year":"2001","journal-title":"Neurology"},{"issue":"7","key":"ref34","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1002\/art.1780370703","article-title":"Treatment of refractory rheumatoid arthritis with a monoclonal antibody to intercellular adhesion molecule 1","volume":"37","author":"AF Kavanaugh","year":"1994","journal-title":"Arthritis and rheumatism"},{"issue":"8","key":"ref35","first-page":"1338","article-title":"A phase I\/II open label study of the safety and efficacy of an anti-ICAM-1 (intercellular adhesion molecule-1; CD54) monoclonal antibody in early rheumatoid arthritis","volume":"23","author":"AF Kavanaugh","year":"1996","journal-title":"The Journal of rheumatology"},{"issue":"5","key":"ref36","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1097\/01.TA.0000030626.84680.11","article-title":"Clinical effects of inhibiting leukocyte adhesion with monoclonal antibody to intercellular adhesion molecule-1 (enlimomab) in the treatment of partial-thickness burn injury","volume":"54","author":"WJ Mileski","year":"2003","journal-title":"The Journal of trauma"},{"issue":"5","key":"ref37","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1002\/art.1780400511","article-title":"Repeat treatment of rheumatoid arthritis patients with a murine anti-intercellular adhesion molecule 1 monoclonal antibody","volume":"40","author":"AF Kavanaugh","year":"1997","journal-title":"Arthritis and rheumatism"},{"issue":"4","key":"ref38","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.4049\/jimmunol.162.4.2353","article-title":"Anti-ICAM-1 monoclonal antibody R6.5 (Enlimomab) promotes activation of neutrophils in whole blood","volume":"162","author":"J Vuorte","year":"1999","journal-title":"Journal of immunology"},{"issue":"20","key":"ref39","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1182\/blood-2014-09-568899","article-title":"Smoldering multiple myeloma","volume":"125","author":"SV Rajkumar","year":"2015","journal-title":"Blood"},{"issue":"21","key":"ref40","doi-asserted-by":"crossref","first-page":"5573","DOI":"10.1182\/blood-2011-01-270140","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM): novel biological insights and development of early treatment strategies","volume":"117","author":"N Korde","year":"2011","journal-title":"Blood"},{"issue":"3","key":"ref41","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1634\/theoncologist.2015-0303","article-title":"The Changing Landscape of Smoldering Multiple Myeloma: A European Perspective","volume":"21","author":"J Caers","year":"2016","journal-title":"The oncologist"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0171205","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T02:19:06Z","timestamp":1692670746000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0171205"}},"subtitle":[],"editor":[{"given":"Robert K","family":"Hills","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,2,3]]},"references-count":41,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2017,2,3]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0171205","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,3]]}}}